Bank of America Reiterates Buy and PT of $40 on NuVasive

by Emily Austin, Benzinga Staff Writer
July 26, 2011 6:24 AM | 19 seconds read |
Bank of America reiterated its Buy rating on NuVasive NUVA. At the same time, the rating agency left its price target on the company's stock unchanged at $40. On Monday, NUVA lost 2.5% of its value to finish the day at $32.36. Its shares continued to slide in today's pre-market trading, falling 1.89% to stand around $31.75.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: ReiterationAnalyst RatingsBank of AmericaHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!